排名前五的靶点	数量

BTK(酪氨酸蛋白激酶BTK)	22
BET(溴结构域和超末端结构蛋白家族)	4
NCOA3(nuclear receptor coactivator 3)	4
GD2(唾液神经节苷脂GD2)	4
FLT3(酪氨酸蛋白激酶受体FLT3)	3

关联

104

项与 Baylor College of Medicine 相关的药物

Zelenoleucel

靶点

NY-ESO-1 x PRAME x WT1

作用机制

NY-ESO-1调节剂 [+4]

在研机构

Marker Therapeutics, Inc. [+1]

原研机构

Marker Therapeutics, Inc.

在研适应症

急性髓性白血病 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

C-188-9

靶点

STAT3

作用机制

STAT3抑制剂

在研机构

Baylor College of Medicine [+4]

原研机构

Baylor College of Medicine

在研适应症

特发性肺纤维化 [+14]

非在研适应症

纤维化 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

multiTAA specific T cells(Baylor College of Medicine)

靶点-

作用机制

细胞替代物

在研机构

Baylor College of Medicine [+1]

原研机构

Baylor College of Medicine

在研适应症

乳腺癌 [+3]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

1,067

项与 Baylor College of Medicine 相关的临床试验

NCT06198296 / Not yet recruiting临床1期IIT

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T Cells

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells.
Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise but have not been strong enough to cure most patients.
In order to get them to kill cancers more effectively, in the laboratory, the study team inserted a new gene called a chimeric antigen receptor (CAR) into T cells that makes them recognize cancer cells and kill them. When inserted, this new CAR T cell can specifically recognize a protein found on solid tumors, called glypican-3 (GPC3). To make this GPC3-CAR more effective, the study team also added two genes called IL15 and IL21 that help CAR T cells grow better and stay in the blood longer so that they may kill tumors better. When the study team did this in the laboratory, they found that this mixture of GPC3-CAR,IL15 and IL21 killed tumor cells better when compared with CAR T cells that did not have IL15 plus IL21 in the laboratory. This study will use those cells, which are called 21.15.GPC3-CAR T cells, to treat patients with solid tumors that have GPC3 on their surface.
The study team also wanted to make sure that they could stop the 21.15.GPC3-CAR T cells from growing in the blood should there be any bad side effects. In order to do so, they inserted a gene called iCasp9 into the FAST-CAR T cells. This allows us the elimination of 21.15.GPC3-CAR T cells in the blood when the gene comes into contact with a medication called AP1903. The drug (AP1903) is an experimental drug that has been tested in humans with no bad side-effects. This drug will only be used to kill the T cells if necessary due to side effects .
The study team has treated patients with T cells that include GPC3. Patients have also been treated with IL-21 and with IL-15. Patients have not been treated with a combination of T cells that contain GPC3, IL-21 and IL-15. To summarize, this study will test the effect of 21.15.GPC3-CAR T cells in patients with solid tumors that express GPC3 on their surface.
The 21.15.GPC3-CAR T cells are an investigational product not yet approved by the Food and Drug Administration.

开始日期2026-01-01

申办/合作机构

Baylor College of Medicine

[+1]

NCT05422469 / Not yet recruitingN/AIIT

Neurobehavioral Investigations of Approach Dynamics in the Ventral Striatum

Traditional strategies for diagnosing psychiatric disorders focus on definitions based on constellations of co-occurring symptoms. Tracking symptom severity across therapy arcs relies on administering scales that again ask questions about symptoms. These strategies have allowed some degree of standardization but suffer from having a phenomenological rather than mechanistic foundation (in terms of diagnosis) as well as subjectivity and temporal sparseness (in terms of measurement). We apply a transdiagnostic framework based on the neurobiological concept of approach behavior. Several psychiatric disorders (including OCD, uni- and bipolar depression, PTSD and anxiety disorders, and addiction disorders) are characterized by dysfunction in approach behavior. We study the neurobehavioral basis of approach dysfunction in a cohort of individuals with severe OCD and bipolar disorder (BD). To study these behaviors, we deploy a suite of wearables and peripherals (Oura ring, Apple Watch, iPhone, audioband) that allow continuous and dense measurement of behaviors relevant to our approach hypothesis: socialization, activity, and sleep patterns. We perform these measurements in two selected environments. One is a novel apartment-style setting (neurobehavioral unit, NBU) that combines the high-bandwidth data acquisition capability of a lab with the naturalistic relevance and comfort of the home. The second is the truly natural and maximally ethologically relevant setting of the ambulatory "home" environment in which people spend the majority of their time. The participants will be individuals planned for deep brain stimulation (DBS) implant for their OCD or BD. The bi-directional (stimulate as well as record) nature of the DBS systems will allow neural recordings that we will synchronize with the behavioral data streams. We will apply predictive computational models in conjunction with the causal manipulation provided by stimulation to test mechanistic hypothesis relating neurophysiology, behavior, and clinical status.

开始日期2025-08-01

申办/合作机构

Baylor College of Medicine

NCT06596447 / Not yet recruitingN/AIIT

Monitoring in Patients That Have Undergone Deep Brain Stimulation (DBS) for Obsessive-Compulsive Disorder (OCD)

The goal of this clinical trial is to develop a mechanistic understanding of ventral-capsule ventral-striatum (VC/VS) deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD). Doing so would allow us to identify and track neural and behavioral biomarkers of clinical status that will demystify programming and inform clinical decision-making. This study involves neurobehavioral collection and analysis of data in OCD patients.
Participants will be followed in clinic for 7 visits where they will complete clinical assessments and participate in behavioral tasks and psychologist-led exposure trials. They will also be asked to participate in naturalistic device tracking, including wearing an Oura Ring and DBS recordings.

开始日期2025-06-01

申办/合作机构

Baylor College of Medicine

100 项与 Baylor College of Medicine 相关的临床结果

登录后查看更多信息

0 项与 Baylor College of Medicine 相关的专利（医药）

登录后查看更多信息

85,009

项与 Baylor College of Medicine 相关的文献（医药）

2025-03-01·Neural Regeneration Research

Enhancement of motor functional recovery in thoracic spinal cord injury: voluntary wheel running versus forced treadmill exercise

Article

作者: Moon, Younghye ; Liu, Nai-Kui ; Cao, Dan ; Chen, Chen ; Xu, Xiao-Ming ; Lee, Do-Hun ; Wu, Wei

JOURNAL/nrgr/04.03/01300535-202503000-00028/figure1/v/2024-06-17T092413Z/r/image-tiff Spinal cord injury necessitates effective rehabilitation strategies, with exercise therapies showing promise in promoting recovery. This study investigated the impact of rehabilitation exercise on functional recovery and morphological changes following thoracic contusive spinal cord injury. After a 7-day recovery period after spinal cord injury, mice were assigned to either a trained group (10 weeks of voluntary running wheel or forced treadmill exercise) or an untrained group. Bi-weekly assessments revealed that the exercise-trained group, particularly the voluntary wheel exercise subgroup, displayed significantly improved locomotor recovery, more plasticity of dopaminergic and serotonin modulation compared with the untrained group. Additionally, exercise interventions led to gait pattern restoration and enhanced transcranial magnetic motor-evoked potentials. Despite consistent injury areas across groups, exercise training promoted terminal innervation of descending axons. In summary, voluntary wheel exercise shows promise for enhancing outcomes after thoracic contusive spinal cord injury, emphasizing the role of exercise modality in promoting recovery and morphological changes in spinal cord injuries. Our findings will influence future strategies for rehabilitation exercises, restoring functional movement after spinal cord injury.

2025-01-01·CLINICA CHIMICA ACTA

Emergency department clinical performance of ADVIA Centaur n-terminal prohormone of B-type natriuretic peptide assay

作者: Januzzi, James L. ; Brown, Chadwick ; Frank Peacock, W. ; Januzzi, James L ; Cooper, Charles K ; Liu Liu, Yan ; Snyder, Jennifer ; Frank Peacock, W

2025-01-01·FOOD CHEMISTRY

Discovery of steroidal alkaloid metabolites and their accumulation in pigs after short-term tomato consumption

Article

作者: Sholola, Maria J. ; Dzakovich, Michael P ; Francis, David M. ; Sholola, Maria J ; Goggans, Mallory L ; Dzakovich, Michael P. ; Goggans, Mallory L. ; Cooperstone, Jessica L ; Jacobi, Sheila K. ; Cooperstone, Jessica L. ; Francis, David M ; Jacobi, Sheila K

Studies suggest steroidal alkaloids contribute to the health properties of tomato-rich diets. Untargeted studies have detected tomato steroidal alkaloid metabolites in plasma, tissues, and urine, but concentrations remain unknown. Here we utilize UHPLC-MS/MS to characterize 31 steroidal alkaloid metabolites representing 10 unique masses, and a validated UHPLC-MS method to quantify them in blood plasma. In a two-week parallel-arm study, piglets (n = 20) were fed diets containing 10 % tomato powder or a macronutrient-matched control. Concentrations averaged to 107.7 nmol/L plasma, comprising of phase I (66 %) and phase II (4.5 %) metabolites. Primary phase I metabolites were hydroxylated isomers. MS/MS fragments (m/z 253, 271, 289) in conjunction with analysis of diet profile provided higher confidence when identifying hydroxylated metabolites. These results are the first to report quantitative levels of steroidal alkaloid metabolites in plasma, contributing to an understanding of physiologically relevant concentrations. This data is useful for contextualizing research on the health benefits of tomatoes.

615

项与 Baylor College of Medicine 相关的新闻（医药）

2024-10-31

·GlobeNewswire-Health Care

Ovid Therapeutics to Host Investor Event

KCC2 Download Day on Wednesday, November 13, 2024NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid’s headquarters in New York’s Hudson Yards from 9:30 to 11:30 am ET and will be webcast simultaneously. The session will focus on the biological relevance and broad potential therapeutic opportunity associated with Ovid’s KCC2 portfolio. Company management will provide updates on the portfolio’s programs, including the first in the franchise, OV350. Recognized thought leaders in neurology and neuropharmacology will present, including: Jeffrey Noebels, M.D., Ph.D. - Cullen Trust for Health Care Endowed Chair in Neurogenetics and Professor of Neurology, Neuroscience, and Molecular and Human Genetics at Baylor College of Medicine, and Director of The Blue Bird Circle Developmental Neurogenetics LaboratoryKarl Kieburtz, M.D., M.P.H. - Professor of Neurology, University of Rochester School of Medicine, and Managing Principal of Clintrex Research LLCStephen Moss, Ph.D. - Director of the Moss Labs for Neuropharmacology within Tufts University Neuroscience Department and Professor of Molecular Pharmacology, Department of Neuroscience, Physiology, and Pharmacology, University College, London Interest in AttendingTo attend in person, contact Ovid Investor Relations at IR@ovidrx.com for registration. Breakfast and lunch will be provided. A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at https://investors.ovidrx.com. About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company that is dedicated to improving the lives of people affected by rare epilepsies and brain conditions. Ovid is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. Ovid is developing: OV888/GV101 capsule, a potent and highly selective rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, for the potential treatment of cerebral cavernous malformations and other rare central nervous system diseases; OV329, a GABA-AT inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the potassium-chloride co-transporter 2 (KCC2), for the potential treatment of epilepsies, neurodegenerative and other psychiatric conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com. Forward- Looking Statements This press release includes certain disclosures by Ovid that contain “forward-looking statements” including, without limitation: the therapeutic potential of any of Ovid’s KCC portfolio, including OV350; the potential therapeutic opportunity of OV888/GV101 capsule, and OV329; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plan,” “potentially,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, the risk that results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 13, 2024, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Investor Relations:Garret Bonneygbonney@ovidrx.com Media:Raquel Caborcabo@ovidrx.com

2024-10-31

·凯莱英Asymchem

【行研】全球市场超百亿美元的热门靶点——BTK

BTK是BCR(B-Cell Receptor，B细胞表面抗原受体)通路的关键激酶，在B细胞抗原受体受体（BCR）的信号传导中起关键作用，而BCR信号通路对于淋巴瘤中恶性B细胞的增殖和存活至关重要。目前已发现BTK 在各种B细胞恶性肿瘤中调节着细胞增殖、存活和迁移等生命活动，BTK靶点已成为最具潜力的涉及B细胞和巨噬细胞活化的靶点之一。自从第一个BTK抑制剂伊布替尼于2013年上市以来，BTK抑制剂在血液瘤中得到了广泛应用，在该领域取得了较大成功，其疗效和安全性都得到了充分的论证，总体销售额已经达到上百亿美元。据公开资料显示，2022年全球BTK抑制剂市场规模为115亿美元，并以接近30%的增速逐年增长；据弗若斯特沙利文数据，全球BTK抑制剂市场规模预计2025年达219亿美元，2030年达251亿美元，中国BTK抑制剂的市场规模将从2022年的43亿元人民币增长至2030年的225亿元，年复合增长率达到33%。明朗和广阔的市场吸引了不少药企入局。图.全球及中国BTK抑制剂市场规模来源：Frost & Sullivan，交银国际业界习惯将BTK划分为3代产品： 1）一代BTKi为共价抑制剂：伊布替尼2013年被FDA批准上市，目前已获批MCL、CLL、WM、MZL、cGVHD共5项适应症； 2）二代BTKi同样为共价抑制剂，相较于一代产品提升了BTK的选择性因此有更好的疗效和安全性，如阿卡替尼、泽布替尼、奥布替尼； 3）三代BTKi为非共价抑制剂，可治疗对前2代BTKi耐药的C481突变。2023年礼来的吡托布替尼（Loxo-305）的3L MCL和3L CLL适应症获FDA加速批准。表1.已上市BTK抑制剂药物情况来源：根据公开资料整理全球市场来看，伊布替尼凭借先发优势和获批适应症最多，2021年达到销售峰值97.8亿美元，2022年源于竞争加剧销售额开始下滑至83.5亿美元（-14.6%）。而阿卡替尼，泽布替尼销售额高速增长，2022年阿卡替尼全球销售额达20.6亿美元（+66.2%），泽布替尼实现全球销售5.7亿美元（+159%），2023年1月泽布海外获批2L CLL/SLL适应症，带动2023前三季度全球销售额达8.7亿美元。国内市场来看，国产药品泽布替尼、奥布替尼二代BTK抑制剂凭借疗效、安全性、价格优势，公立医院市占率不断提升，且纳入医保巨额提升销售放量。以奥布替尼为例，2022年奥布替尼进入医保后，国内城市公立医院市占率从2021年2.8%提升至6.5%，截至2023上半年，市占率达12.1%。图左. 全球BTK靶点研发阶段概况图右. 中国BTK靶点研发阶段概况来源：医药魔方 2024年4月23日，赛诺菲宣布BTK 抑制剂Rilzabrutinib（SAR444671/PRN-1008）治疗持续性或慢性免疫性血小板减少症（ITP）成年患者的III期LUNA 3研究达到主要终点，并计划于今年年底前向FDA递 Rilzabrutinib的上市申请。如若Rilzabrutinib顺利获批，将成为全球第7款上市的BTK抑制剂，与已获批的BTK抑制剂的适应症不同，赛诺菲的Rilzabrutinib以ITP作为首发适应症，将是全球首款获批ITP适应症的BTK抑制剂。目前BTK抑制剂的研发方向主要为非共价BTK抑制剂，适应症也从血液瘤拓展到自免领域拓展，药物类型从小分子延伸到PROTACs类。在非共价BTK抑制剂研究领域，基于非共价的优势，目前全球的非共价（可逆）BTK抑制剂赛道也聚集了诸多企业，已有多款药物进入临床试验阶段，如LOXO-305、MK-1026、BN102（AS-1763）、HMPL-760。在适应症方面，BTK抑制剂已被证明治疗自身免疫疾病和炎症临床有效，包括原发免疫性血小板减少症（ITP）、系统性红斑狼疮（SLE）、多发性硬化症（MS）、类风湿性关节炎（Rheumatoid arthritis,RA）等，当前BTK抑制剂在自免领域的研发正如火如荼地进行。据华创证券统计，目前在自身免疫性疾病领域探索的BTK抑制剂超过20款，适应症聚焦在多发性硬化症（MS）、自发性荨麻疹、系统性红斑狼疮、类风湿性关节炎等疾病。除诺华的Remibrutinib，赛诺菲的另一款BTK抑制剂Tolebrutinib瞄准了MS，目前也在临床Ⅲ期；渤健针对MS的BIB091，艾伯维针对系统性红斑狼疮、类风湿关节炎的Elsubrutinib都已进入临床Ⅱ期。在药物类型方面，目前国内外已有多家企业开发的BTK-PROTAC进入临床阶段。NX-2127由Nurix Therapeutic开发，是first-in-class的口服BTK降解剂，目前在开展针对B细胞恶性肿瘤临床试验Ⅰ期。此外，国外还有Baylor College of Medicine开发的RC-1；Yale University的MT-802也是BTK-PROTAC产品；国内有海思科自主开发的HSK29116、百济神州开发的BGB-16673等产品。整体来说，全球针对BTK-PROTACs的临床实验尚在早期阶段，但若能成功上市，有效解决BTK患者的耐药难题， PROTACs或将成为BTK抑制剂的焦点。 References 参考资料 1.https://baijiahao.baidu.com/s?id=1774822688581233271&wfr=spider&for=pc 2.https://baijiahao.baidu.com/s?id=1798716367638420557&wfr=spider&for=pc 3.平安证券 -始于创新、强于执行力，血液瘤及自免领域管线双开花20240321 4.https://news.yaozh.com/archive/42009 5.https://xueqiu.com/6410972106/288071404?_ugc_source=ugcbaiducard

上市批准加速审批医药出海细胞疗法

2024-10-30

·PRNewswire

The Inner Circle acknowledges, Steven Lorch as a Pinnacle Life Member

HOUSTON, Oct. 30, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Steven Lorch is acknowledged as a Pinnacle Life Member for his contributions to the field of Pediatric Cardiology. Dr. Lorch attended Emory University in Atlanta where he received a Bachelor of Science degree. He earned a medical degree from Emory University, School of Medicine; completed a residency in pediatrics at Baylor College of Medicine/Texas Children's Hospital; a fellowship in pediatric cardiology at Washington University/St. Louis Children's Hospital. Board-certified in pediatric cardiology, Dr. Lorch explained that as a pediatric cardiologist, he sees infants, young children, and adolescents on an outpatient basis. He treats children for cardiac abnormalities, heart murmurs, tachycardia, and palpitations and works closely with the families and parents of these children, educating them on their conditions. A proven professional, Dr. Lorch specializes in caring for fetuses, infants, children and adolescents with cardiovascular or cardiac abnormalities. He is experienced in both inpatient and outpatient settings and explained that the scope of conditions cared for by pediatric cardiologists is large and includes congenital heart defects; heart muscle disorders; rhythm disturbances; and hypertension. He said that pediatric cardiology is a medical specialty that involves the evaluation, diagnosis, and treatment of congenital (present at birth) and acquired cardiovascular (heart and blood vessel) problems of the fetus, infant, child, adolescent, and young adults. Pediatric cardiologists, like Dr. Lorch, diagnose and treat children with heart conditions before they are born; through childhood; and into adulthood. His clinical interests include pediatric and congenital heart disease, fetal echocardiography, and preventive cardiology. Dedicated to professional networking and staying abreast of the latest innovations in his field, Dr. Lorch is affiliated with Woman's Hospital of Texas; Memorial Hermann Memorial City Medical Center; Memorial Hermann Katy Hospital; Memorial Hermann Northeast Hospital; Memorial Hermann Sugar Land Hospital; and St. Joseph Health College Station Hospital. Prior to his post at Pediatrix Cardiology of Houston, Dr. Lorch served as assistant head of the Pediatric Echocardiography Laboratory at the University of Texas Health Science Center in Houston. He is a Diplomate of the American Board of Pediatrics (ABP) and explained that the mission of the ABP is to advance child health by certifying pediatricians who meet standards of excellence and are committed to continuous learning and improvement. The doctor is a member of the American Society of Echocardiography; American College of Cardiology; Harris County Medical Society; Texas Medical Association. When considering his success, Dr. Lorch notes that his mentors include Achiau Ludomirsky, MD who was his mentor and division director in St. Louis. Aside from his professional pursuits, Dr. Lorch is a parent volunteer with the Boy Scouts of America Troop 55 in Houston. He has been married to Mrs. Clare Gentry for 22 years and they have one son and daughter. For more information about Dr. Lorch's practice, please visit his website at . Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

100 项与 Baylor College of Medicine 相关的药物交易

登录后查看更多信息

100 项与 Baylor College of Medicine 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Mesenchymal stem cells(Baylor College of Medicine)	SARS-CoV-2 急性呼吸道疾病更多	临床1/2期
SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells(Baylor College of Medicine)	神经母细胞瘤更多	临床1/2期
Sm-TSP-2	曼氏血吸虫病更多	临床1/2期
Allogeneic anti-GPC3｜IL15｜IL21 CAR-T (Baylor College of Medicine) ( GPC3 x IL-15 x IL-21 )	肝细胞癌更多	临床1期
C7R-GD2.CART cell therapy(Baylor College of Medicine) ( GD2 )	Ⅱ型戈谢病更多	临床1期